Syndax Pharmaceuticals

Company snapshot

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include a menin inhibitor for R/R acute leukemia and a monoclonal antibody that blocks the CSF-1 receptor for chronic graft-versus-host disease. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its p

• 1 approved product(s) across US/EU regulatory metadata.
• 47 active pipeline program(s) linked via ClinicalTrials.gov.
• 6 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Syndax Pharmaceuticals. Not investment advice.

• trial_data Jun 8, 2026

  Syndax pipeline update: Revuforj and Niktimvo catalysts to watch

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 40

• Peer + 0 momentum

  ALX ONCOLOGY HOLDINGS

  TA overlap score 32.6

• Peer + 0 momentum

  ADC Therapeutics

  TA overlap score 26

• Peer + 0 momentum

  Shanghai Medical College

  TA overlap score 24

• Peer + 0 momentum

  Peking University Biologics

  TA overlap score 23

• Peer + 0 momentum

  Zentalis Pharmaceuticals

  TA overlap score 22.8

• Peer + 0 momentum

  ME Therapeutics

  TA overlap score 22.6

• Peer + 0 momentum

  Prelude Therapeutics

  TA overlap score 22.6

• Peer + 0 momentum

  Provectus Biopharmaceuticals

  TA overlap score 22.4

• Peer + 0 momentum

  Actinium Pharmaceuticals

  TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for Syndax Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   SNDX-5613-0710 — Phase 3

2. Jun 8, 2026 Clinical update

   SNDX-5613-0708 — Phase 1

3. Jun 8, 2026 Clinical update

   SNDX-5613-0700 — Phase 2

4. Jun 8, 2026 Clinical update

   AXATILIMAB — Phase 2

5. Jun 8, 2026 Clinical update

   Revumenib — Phase 1

View all clinical trial activity →

• What is Syndax Pharmaceuticals?

  Syndax Pharmaceuticals is a pharma organization headquartered in New York, USA. Primary therapeutic focus areas include Acute Myeloid Leukemias, Breast Cancer, Acute Myeloid Leukemia, Relapsed or Refractory Acute Leukemias, Chronic Graft-versus-host-disease. NovaPharmaNews links

• Is Syndax Pharmaceuticals publicly traded?

  Syndax Pharmaceuticals appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Syndax Pharmaceuticals develop or market?

  We link 29 drug profile(s) where Syndax Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/syndax-pharmaceuticals-inc#company-drugs.

• What are the latest developments for Syndax Pharmaceuticals?

  In the last 12 months our linked public records show 47 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Syndax Pharmaceuticals focus on?

  Syndax Pharmaceuticals focuses on Acute Myeloid Leukemias, Breast Cancer, Acute Myeloid Leukemia based on our analysis of their pipeline programs and drug development activities.